Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGuIX nanoparticles with radiotherapy and temozolomide in newly diagnosed glioblastoma
2024-517114-15-00Phase 2Authorised
- Sponsor
- Centre Jean Perrin
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of AGuIX in glioblastoma (GBM), sponsored by Centre Jean Perrin. Primary endpoints: Recommended dose of AGuIX (Phase I) and 6-month progression-free survival rate (Phase II). Planned start Jan 2025; status: authorised.
02
Drugs
AGuIX
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-517114-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517114-15-00.